Here we describe the properties of CP-154,526, a potent and selective nonpeptide antagonist of corticotropin (ACTH) releasing factor (CRF) receptors. CP-154,526 binds with high affinity to CRF receptors (K; < 10 nM) and blocks CRF-stimulated adenylate cyclase activity in membranes prepared from rat cortex and pituitary. Systemically administered CP-154,526 antagonizes the stimulatory effects of exogenous CRF on plasma ACTH, locus coeruleus neuronal firing and startle response amplitude. Potential anxiolytic activity of CP-154,526 was revealed in a fearpotentiated startle paradigm. These data are presented in the context of clinical findings, which suggest that CRF is hypersecreted in certain pathological states. We propose that a CRF antagonist such as CP-154,526 could affirm the role of CRF in certain psychiatric diseases and may be of significant value in the treatment of these disorders.
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Corticotropin releasing factor (CRF) is a 41-amino acid peptide initially identified as a hypothalamic factor responsible for stimulating corticotropin (ACTH) secretion from the anterior pituitary (1, 2) . CRF causes a rapid increase in plasma ACTH and glucocorticoid levels when given intravenously (3) . Activation of the hypothalamic-pituitary-adrenal (HPA) axis can also result from release of CRF from the paraventricular nucleus of the hypothalamus in response to various stressors (1, 4) . In the central nervous system, both CRF-like immunoreactivity and high affinity CRF receptors are heterogeneously distributed in the brain (5, 6) . Characterizations of these extrahypothalamic CRF systems demonstrate that, in parallel with its actions on the HPA axis, CRF also acts as a neurotransmitter or neuromodulator to coordinate stress-induced neural responses in the brain (7, 8) .
Intracerebroventricular administration of CRF to rats leads to a constellation of neurochemical, neurophysiological, and behavioral sequelae that include activation of central noradrenergic systems and enhancement of behavioral responses to external stimuli (9) (10) (11) (12) (13) . In this regard, increases in norepinephrine turnover (10) and in the firing rate of locus coeruleus neurons (13) have been observed following CRF injection. Physiological stressors such as nitroprusside infusions also increase locus coeruleus neuronal firing, an effect blocked by a CRF antagonist (a-helical CRF9-41) and consequently thought to be mediated by endogenous CRF (14, 15) . The response to hemodynamic stress in this case can be desensitized by chronic treatment with tricyclic antidepressants, suggesting that one possible mode of action of antidepressants might be to alter central CRF neurotransmission (16) . In behavioral paradigms, CRF injection i.c.v. produces anxiogenic-like effects in several rodent models (e.g. [17] [18] [19] [20] . These effects are antagonized by central infusion of peptide antagonists (a-helical CRF9-41 and D-Phe CRF12-41), suggesting the involvement of CRF in anxiety and the utility of CRF antagonists as anxiolytics. The persistence ofbehavioral activation in hypophysectomized and dexamethasone-treated rats reinforces the notion that it occurs independent of the HPA axis (21) .
Various clinical findings suggest that CRF is hypersecreted in certain pathological states. For example, cerebrospinal fluid levels of CRF are elevated in chronically depressed patients (22, 23) but return toward normal 24 h after a course of treatment with electroconvulsive therapy (24) . Dexamethasone nonsuppression, the failure of an exogenously administered glucocorticoid to lower cortisol levels, is observed in 40% of depressed patients and is consistent with hyperactivity of the HPA axis in this population (25) . Elevations in neuronal CRF activity result in the down-regulation of CRF receptors, which could underlie the blunted ACTH response to i.v. CRF observed in depressed patients, bulimics, and victims of childhood sexual abuse (26) (27) (28) . CRF receptor densities postmortem are in fact diminished in the brains of suicide victims, supporting the hypothesis that brain CRF systems may be hyperactive in individuals suffering from severe melancholia (29) . Although changes in HPA function may result from hypersecretion of CRF, studies in primates have shown that a major component of CRF release in brain appears to be extrahypothalamic in origin in that cerebrospinal fluid levels of CRF do not correlate with HPA axis activity (30) .
While a CRF antagonist may be useful in treating some forms of psychiatric illness, it is likely that a peptide such as a-helical CRF9 41 would have limited utility due to poor bioavailability and difficulty in penetrating the blood-brain barrier. Therefore, we sought to identify a nonpeptide CRF receptor antagonist for potential use as a therapeutic agent. Here we describe the properties of CP-154,526, the first potent, selective nonpeptide CRF antagonist. In addition, data are presented indicating that this unique compound exhibits anxiolytic potential in animals.
MATERIALS AND METHODS
Receptor Binding. Assays were modified from those described previously (31 Acoustic Startle. Male Sprague-Dawley rats were used as subjects. Startle experiments were conducted using previously described equipment (35) . In the CRF-enhanced startle experiments, rats were implanted with intracerebroventricular cannulae 1 week after arrival. Four days later, subjects were exposed to 20 120-dB[A] acoustic startle stimuli, interspersed by 15 sec of background noise. Results from this baseline matching test were used to assign treament groups. Two days later, rats were exposed to two startle sessions, one before administration of drugs and one afterward. The first session consisted of 60 trials as described above and served as a reference for the startle amplitudes measured after drug administration. Because the results were not significantly different after normalization than when absolute startle amplitudes were analyzed, only the absolute startle scores after drug administration are reported here. After the first startle session, rats were administered rat/human CRF ( experiments, CRF activated adenylate cyclase in rat cortical membranes in a concentration-dependent manner ( Fig. 2  inset) ; a challenge concentration of 100 nM oCRF was then selected to establish antagonist potency. Like a-helical oCRF9A4l, CP-154,526 completely blocked the activation of adenylate cyclase caused by 100 nM oCRF ( Fig. 2) with an apparent K1 of 3.7 nM (geometric mean of 3 experiments = -8.43 ± 0.1). CP-154,526 alone did not alter basal or forskolin-stimulated adenylate cyclase. Moreover, it did not affect activation of adenylate cyclase mediated by histamine H2 or noradrenergic f3 receptors in rat brain (data not shown), indicating that its ability to block CRF-stimulated adenylate cyclase activity is due to a specific antagonism of CRF receptors.
Blockade of CRF-Induced ACTH Secretion. To examine the effect of CP-154,526 on CRF receptors in vivo, changes in plasma ACTH were determined in rats administered a challenge dose of 4 ,ug/kg oCRF i.v. Previous studies have shown that this dose elicits a half-maximal increase in plasma ACTH levels measured 30 min later (3). As shown in Fig. 3 (13) . Onset of the excitation occurred within the first 2 min following injection; times to peak effects were variable, occasionally requiring 10-15 min (Fig. 4A) . Injection i.c.v. with the CRF vehicle (0.5N HCl) did not alter baseline neuronal activity. Repeated administration of CRF to the same neuron gave generally smaller increases in excitation, a finding noted previously by others (44) .
In a separate series of experiments, intravenous administration of CP-154,526 5-10 min prior to the CRF challenge blocked the excitation in a dose-dependent manner (Fig. 4) Selectivity of the blockade by CP-154,526 was probed with substance P-induced excitation of locus coeruleus cell firing. Substance P given alone (1.0 ,ug in 6.0 ptl of saline i.c.v.) increased firing rate by 102 ± 28% (mean ± SEM, n = 4). During the same recording session, CP-154,526 at 5.6 mg/kg i.v., the highest dose tested against the CRF challenge, was ineffective at blocking the response to substance P (net excitation = 101 + 11%).
Blockade of CRF-Enhanced and Fear-Potentiated Acoustic Startle. Fig. 5 illustrates the effects of i.c.v. CRF on acoustic startle. As reported previously, (12, 19, 20) D-Phe CRF1241 produced no effect on startle when given alone. In earlier reports (12, 20) , a-helical oCRF9-41 at doses A of 25-50 ,ug antagonized the startle-enhancing effects of CRF. That we observed full blockade of the CRF effect with a D-Phe CRF12-41 dose of 3.2 ,ug agrees with its greater potency in other behavioral procedures (45) .
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CONCLUDING REMARKS
In earlier reports, the stimulation of locus coeruleus cell firing by CRF has served as evidence for a hypothesized role for this peptide in modulating noradrenergic tone during periods of stress (14, 15) . A dampening of this system by a CRF antagonist would mimic the action of chronic treatment with tricyclic antidepressants in attenuating stress-induced locus coeruleus activation (16) . To increased fear or anxiety, as administration of the anxiolytic chlordiazepoxide blocks the effect of CRF but not the startleincreasing effects of amphetamine or strychnine (19) . Moreover, lesions of the amygdala, a key limbic structure in the mediation of fear and anxiety responses to stressors, abolish potentiated startle (47) . Several classes of anxiolyic-like drugs also block potentiated startle (see review by Davis, ref. 48) , and peptide CRF antagonists are known to be effective in other models of anxiety (e.g. ref. 45 ). Consequently, it is possible that a CRF antagonist would be a useful medication in the treatment of some disorders in which anxiety is a prominent feature.
In conclusion, CP-154,526 is the first nonpeptide antagonist of CRF receptors and possesses clear pharmaceutical advantages over peptide antagonists. CP-154,526 potently and selectively blocks CRF receptor-mediated activity in vitro as shown in adenylate cyclase assays and attenuates the activation of the HPA axis caused by exogenous CRF. CP-154,526 readily enters the CNS following peripheral administration, as demonstrated by its ability to antagonize the electrophysiological and behavioral effects of CRF infused directly into the brain.
The finding that CP-154,526 is highly selective for the CRF1 receptor subtype, coupled with the observation that CP-154,526 almost completely blocks the effects of CRF in all systems reported here, strongly suggests that these actions of CRF are mediated exclusively by the CRF1 receptor subtype. Taken together, these data suggest that CP-154,526 will serve as a useful tool for further probing the functional importance of brain CRF systems. In the clinic, CP-154,526 may have important therapeutic utility in treating depression and anxiety as well as other diseases where excessive stimulation of CRF receptors contributes to pathology.
